title: Fluoroquinolones in the treatment of cystic fibrosis.
abstract: Cystic fibrosis patients suffer from recurrent and chronic lung infections mainly caused by Staphylococcus aureus, Haemophilus influenzae and Pseudomonas aeruginosa. The fluoroquinolones, notably ciprofloxacin and ofloxacin, represent an important addition to the therapy of P. aeruginosa infections. They offer the possibility of effective oral treatment for early colonisation as well as chronic infections, even in children. They are associated with only few and mild adverse effects. Development of resistance represents an increasing problem.
authors.affiliation: Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark.
authors.forename: N
authors.initials: N
authors.lastname: Høiby
authors.forename: S S
authors.initials: SS
authors.lastname: Pedersen
authors.forename: T
authors.initials: T
authors.lastname: Jensen
authors.forename: N H
authors.initials: NH
authors.lastname: Valerius
authors.forename: C
authors.initials: C
authors.lastname: Koch
mesh_terms: D002939:Ciprofloxacin / Q000627:therapeutic use*; D003550:Cystic Fibrosis / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D015242:Ofloxacin / Q000627:therapeutic use*; D011552:Pseudomonas Infections / Q000517:prevention & control
chemical_list: D002939:Ciprofloxacin; D015242:Ofloxacin